| ￥3300 | |
| Z06185-100 | |
|
|
|
|
|
|
|
|
|
| Species | Mouse | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 37.55 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 45-60 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
| Target Background | Two type 1 membrane proteins belonging to the hemopoietin receptor family have been cloned and shown to bind IL-13 with differing affinities. The lower affinity IL-13 binding protein, previously designated IL-13 R alpha, IL-13 R alpha ' or NR4, is now referred to as IL-13 R alpha 1. The high-affinity IL-13 binding protein, previously also designated IL-13 R or IL-13 R alpha ', is now referred to as IL-13 R alpha 2. |
| Synonyms | CD213a2; IL-13 R alpha 2; IL13BP; IL13R; IL13RA2; IL-13Ra2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
